TICAM1 and cancer: For example, Eritoran has previously been shown to prevent TLR4/TRIF-dependent signalling.19 However, these candidates failed in different stages of clinical trials.20,21 Therefore, the generation of novel TLR4 modulators, which are in different stages of pre-clinical or clinical validation, will be beneficial for the treatment in a broad range of inflammatory-related diseases including cancer.22